Song Yi, He Zhi-song, Li Ning-chen, Li Ming, Zhou Li-qun, Na Yan-qun
Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China.
Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10):678-80.
To investigate the prognosis of surgical treatment for renal cell carcinoma with renal vein or inferior vena cava tumor thrombus.
Between August 1994 and July 2004, 33 patients with renal cell carcinoma with renal vein or inferior vena cava tumor thrombus underwent radical nephrectomy and thrombectomy. The study population included 26 male and 7 female. The median age was 60 years (20 - 82). Level of tumor thrombus was renal vein in 15 patients, infrahepatic (level I) in 9, intrahepatic (level II) in 5, suprahepatic (level III) in 1, and right atrial extension (level IV) in 3. Survival analysis was made with Kaplan-Meier method.
Twenty-nine patients can be followed up. Fourteen patients were lost with a mean survival time of (16.4 +/- 2.9) months (1 - 42 months). Fifteen patients were survival with a mean follow-up of (17.3 +/- 4.6) months (3 - 67 months). One patient was lost on the second postoperative day. Three patients can not be followed up. The 5-year Kaplan-Meier survival rate was 16%. The mean survival time of patients with renal vein involvement [(49.9 +/- 9.8) months] versus level I [(16.7 +/- 1.9) months] was significantly different (P < 0.05).
Radical nephrectomy plus thrombectomy is a valuable method for the treatment of renal cell carcinoma with renal vein or inferior vena cava involvement. Patients with renal vein tumor thrombus appear to have better survival compared to patients with inferior vena cava tumor thrombus.
探讨肾细胞癌伴肾静脉或下腔静脉瘤栓手术治疗的预后。
1994年8月至2004年7月,33例肾细胞癌伴肾静脉或下腔静脉瘤栓患者接受了根治性肾切除术及瘤栓切除术。研究人群包括26例男性和7例女性。中位年龄为60岁(20 - 82岁)。肿瘤栓子水平为肾静脉者15例,肝下(I级)9例,肝内(II级)5例,肝上(III级)1例,右心房延伸(IV级)3例。采用Kaplan-Meier法进行生存分析。
29例患者可进行随访。14例失访,平均生存时间为(16.4±2.9)个月(1 - 42个月)。15例存活,平均随访时间为(17.3±4.6)个月(3 - 67个月)。1例患者术后第2天失访。3例患者无法随访。5年Kaplan-Meier生存率为16%。肾静脉受累患者的平均生存时间[(49.9±9.8)个月]与I级患者[(16.7±1.9)个月]相比有显著差异(P < 0.05)。
根治性肾切除术加瘤栓切除术是治疗肾细胞癌伴肾静脉或下腔静脉受累的一种有价值的方法。与下腔静脉瘤栓患者相比,肾静脉瘤栓患者似乎有更好的生存率。